
    
      OUTLINE:

      Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-21 and
      pembrolizumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days for up
      to 2 years in the absence of disease progression or unacceptable toxicity. Disease assessment
      by imaging will be performed every 9 weeks.
    
  